Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Sample Collection and Processing
2.3. cfDNA Extraction and Quantification
2.4. Sequencing Library Preparation
2.5. Genome-Wide Next-Generation Sequencing
2.6. Sequencing Data Analysis
2.7. Statistical Analysis
3. Results
3.1. Patient Population
3.2. GIN Is Measurable in the Plasma of Metastatic Breast Cancer Patients
3.3. GIN Scores at Baseline Are Associated with Survival
3.4. Early On-Treatment GIN Scores Are Associated with Treatment Response and Outcome
3.5. Early GIN Score Changes during Treatment
3.5.1. Baseline vs. T1
3.5.2. Baseline vs. T2
3.5.3. T2 vs. T1 and GIN Patterns
3.6. GIN Is Higher and Decreases More Dramatically in TNBC Patients
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Largillier, R.; Ferrero, J.-M.; Doyen, J.; Barriere, J.; Namer, M.; Mari, V.; Courdi, A.; Hannoun-Levi, J.M.; Ettore, F.; Birtwisle-Peyrottes, I.; et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann. Oncol. 2008, 19, 2012–2019. [Google Scholar] [CrossRef]
- Kennecke, H.; Yerushalmi, R.; Woods, R.; Cheang, M.C.U.; Voduc, D.; Speers, C.H.; Nielsen, T.O.; Gelmon, K. Metastatic Behavior of Breast Cancer Subtypes. J. Clin. Oncol. 2010, 28, 3271–3277. [Google Scholar] [CrossRef]
- Eng, L.G.; Dawood, S.; Sopik, V.; Haaland, B.; Tan, P.S.; Warner, E.; Iqbal, J.; Narod, S.A.; Bhoo-Pathy, N.; Dent, R. Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res. Treat. 2016, 160, 145–152. [Google Scholar] [CrossRef]
- Chen, M.-T.; Sun, H.-F.; Zhao, Y.; Fu, W.-Y.; Yang, L.-P.; Gao, S.-P.; Li, L.-D.; Jiang, H.-L.; Jin, W. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: A SEER population-based analysis. Sci. Rep. 2017, 7, 1–8. [Google Scholar] [CrossRef] [Green Version]
- Murthy, R.K.; Loi, S.; Okines, A.; Paplomata, E.; Hamilton, E.; Hurvitz, S.A.; Lin, N.U.; Borges, V.; Abramson, V.; Anders, C.; et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N. Engl. J. Med. 2020, 382, 597–609. [Google Scholar] [CrossRef] [PubMed]
- Modi, S.; Saura, C.; Yamashita, T.; Park, Y.H.; Kim, S.B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N. Engl. J. Med. 2020, 382, 610–621. [Google Scholar] [CrossRef]
- Ignatiadis, M.; Sledge, G.W.; Jeffrey, S.S. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat. Rev. Clin. Oncol. 2021, 1–16. [Google Scholar] [CrossRef]
- Garcia-Murillas, I.; Schiavon, G.; Weigelt, B.; Ng, C.; Hrebien, S.; Cutts, R.J.; Cheang, M.; Osin, P.; Nerurkar, A.; Kozarewa, I.; et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 2015, 7, 33. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Murillas, I.; Chopra, N.; Comino-Méndez, I.; Beaney, M.; Tovey, H.; Cutts, R.J.; Swift, C.; Kriplani, D.; Afentakis, M.; Hrebien, S.; et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019, 5, 1473–1478. [Google Scholar] [CrossRef]
- US Food and Drug Administration. FoundationOne® Liquid CDx (F1 Liquid CDx). FDA. Available online: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S017A.pdf (accessed on 10 March 2021).
- Siravegna, G.; Mussolin, B.; Buscarino, M.; Corti, G.; Cassingena, A.; Crisafulli, G.; Ponzetti, A.; Cremolini, C.; Amatu, A.; Lauricella, C.; et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 2015, 21, 795–801. [Google Scholar] [CrossRef] [Green Version]
- Morgensztern, D.; Politi, K.; Herbst, R.S. EGFR Mutations in Non–Small-Cell Lung Cancer: Find, Divide, and Conquer. JAMA Oncol. 2015, 1, 146–148. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cavallone, L.; Aguilar-Mahecha, A.; Lafleur, J.; Brousse, S.; Aldamry, M.; Roseshter, T.; Lan, C.; Alirezaie, N.; Bareke, E.; Majewsk, J.; et al. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci. Rep. 2020, 10, 14704. [Google Scholar] [CrossRef] [PubMed]
- Basik, M.; Aguilar-Mahecha, A.; Rousseau, C.; Diaz, Z.; Tejpar, S.; Spatz, A.; Greenwood, C.M.; Batist, G. Biopsies: Next-generation biospecimens for tailoring therapy. Nat. Rev. Clin. Oncol. 2014, 10, 437–450. [Google Scholar] [CrossRef]
- Murtaza, M.; Dawson, S.J.; Pogrebniak, K.; Rueda, O.M.; Provenzano, E.; Grant, J.; Chin, S.F.; Tsui, D.W.Y.; Marass, F.; Gale, D.; et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun. 2015, 6, 8760. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jensen, T.J.; Goodman, A.M.; Kato, S.; Ellison, C.K.; Daniels, G.A.; Kim, L.; Nakashe, P.; McCarthy, E.; Mazloom, A.R.; McLennan, G.; et al. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Mol. Cancer Ther. 2019, 18, 448–458. [Google Scholar] [CrossRef] [Green Version]
- Ellison, C.K.; Sun, Y.; Hogg, G.; Fox, J.; Tao, H.; McCarthy, E.; Sagoe, B.; Azab, M.A.; Mazloom, A.R.; Tynan, J.; et al. Using Targeted Sequencing of Paralogous Sequences for Noninvasive Detection of Selected Fetal Aneuploidies. Clin. Chem. 2016, 62, 1621–1629. [Google Scholar] [CrossRef]
- Xu, X.; Yu, Y.; Shen, M.; Liu, M.; Wu, S.; Liang, L.; Huang, F.; Zhang, C.; Guo, W.; Liu, T. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. BMC Cancer 2020, 20, 1006. [Google Scholar] [CrossRef]
- Namløs, H.M.; Boye, K.; Mishkin, S.J.; Barøy, T.; Lorenz, S.; Bjerkehagen, B.; Stratford, E.W.; Munthe, E.; Kudlow, B.A.; Myklebost, O.; et al. Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor. Mol. Cancer Ther. 2018, 17, 2473–2480. [Google Scholar] [CrossRef] [Green Version]
- Davis, A.A.; Jacob, S.; Gerratana, L.; Shah, A.N.; Wehbe, F.; Katam, N.; Zhang, Q.; Flaum, L.; Siziopikou, K.P.; Platanias, L.C.; et al. Landscape of circulating tumour DNA in metastatic breast cancer. EBioMedicine 2020, 58, 102914. [Google Scholar] [CrossRef]
- Marchetti, A.; Palma, J.F.; Felicioni, L.; De Pas, T.M.; Chiari, R.; Del Grammastro, M.; Filice, G.; Ludovini, V.; Brandes, A.A.; Chella, A.; et al. Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. J. Thorac. Oncol. 2015, 10, 1437–1443. [Google Scholar] [CrossRef] [Green Version]
- Goldberg, S.B.; Narayan, A.; Kole, A.J.; Decker, R.H.; Teysir, J.; Carriero, N.J.; Lee, A.; Nemati, R.; Nath, S.K.; Mane, S.M.; et al. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin. Cancer Res. 2018, 24, 1872–1880. [Google Scholar] [CrossRef] [Green Version]
- O’Leary, B.; Hrebien, S.; Morden, J.P.; Beaney, M.; Fribbens, C.; Huang, X.; Liu, Y.; Bartlett, C.H.; Koehler, M.; Cristofanilli, M.; et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat. Commun. 2018, 9, 896. [Google Scholar]
- Ma, C.X.; Bose, R.; Gao, F.; Freedman, R.A.; Telli, M.L.; Kimmick, G.; Winer, E.; Naughton, M.; Goetz, M.P.; Russell, C.; et al. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin. Cancer Res. 2017, 23, 5687–5695. [Google Scholar] [CrossRef] [Green Version]
- Hrebien, S.; Citi, V.; Garcia-Murillas, I.; Cutts, R.; Fenwick, K.; Kozarewa, I.; McEwen, R.; Ratnayake, J.; Maudsley, R.; Carr, T.; et al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann. Oncol. 2019, 30, 945–952. [Google Scholar] [CrossRef]
- Weigman, V.J.; Chao, H.H.; Shabalin, A.A.; He, X.; Parker, J.S.; Nordgard, S.H.; Grushko, T.; Huo, D.; Nwachukwu, C.; Nobel, A.; et al. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res. Treat. 2012, 133, 865–880. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61–70. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dawson, S.-J.; Tsui, D.W.; Murtaza, M.; Biggs, H.; Rueda, O.M.; Chin, S.-F.; Dunning, M.J.; Gale, D.; Forshew, T.; Mahler-Araujo, B.; et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. N. Engl. J. Med. 2013, 368, 1199–1209. [Google Scholar] [CrossRef] [Green Version]
- Boonstra, P.A.; Wind, T.T.; van Kruchten, M.; Schuuring, E.; Hospers, G.A.P.; van der Wekken, A.J.; de Groot, D.J.; Schröder, C.P.; Fehrmann, R.S.N.; Reyners, A.K.L. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. Cancer Metastasis Rev. 2020, 39, 999–1013. [Google Scholar] [CrossRef] [PubMed]
- Rowe, S.P.; Luber, B.; Makell, M.; Brothers, P.; Santmyer, J.; Schollenberger, M.D.; Quinn, H.; Edelstein, D.L.; Jones, F.S.; Bleich, K.B.; et al. From validity to clinical utility: The influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol. Oncol. 2018, 12, 1661–1672. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Aguilar-Mahecha, A.; Lafleur, J.; Brousse, S.; Savichtcheva, O.; Holden, K.A.; Faulkner, N.; McLennan, G.; Jensen, T.J.; Basik, M. Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients. Cancers 2021, 13, 1331. https://doi.org/10.3390/cancers13061331
Aguilar-Mahecha A, Lafleur J, Brousse S, Savichtcheva O, Holden KA, Faulkner N, McLennan G, Jensen TJ, Basik M. Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients. Cancers. 2021; 13(6):1331. https://doi.org/10.3390/cancers13061331
Chicago/Turabian StyleAguilar-Mahecha, Adriana, Josiane Lafleur, Susie Brousse, Olga Savichtcheva, Kimberly A. Holden, Nathan Faulkner, Graham McLennan, Taylor J. Jensen, and Mark Basik. 2021. "Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients" Cancers 13, no. 6: 1331. https://doi.org/10.3390/cancers13061331